Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes

Current Diabetes Reports

Volumn 13, Issue 1, 2013, Pages 114-120

  Baldwin, David ^a   Apel, Jill ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic renal failure; End stage renal failure; Glucocorticoid induced diabetes; Glycemic control; Hospitalized diabetes; Hypoglycemia; Inpatient diabetes; Insulin glargine; Renal insufficiency; Steroid induced diabetes

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INTERMEDIATE ACTING INSULIN; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PREDNISONE; SHORT ACTING INSULIN; STEROID; SULFONYLUREA; TACROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD GLUCOSE MONITORING; CANCER SURVIVAL; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; GLOMERULUS FILTRATION RATE; GLUCOCORTICOID INDUCED DIABETES; GLUCOCORTICOID INDUCED HYPERGLYCEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN CLEARANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; LOW DRUG DOSE; MORNING DOSAGE; NEW ONSET DIABETES AFTER TRANSPLANT; NEW ONSET HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONKETOTIC DIABETIC COMA; POSTOPERATIVE COMPLICATION; REHYDRATION; RISK FACTOR; SIDE EFFECT; STEROID INDUCED DIABETES;

DIABETES MELLITUS; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; RENAL INSUFFICIENCY; STEROIDS;

EID: 84872595570     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0339-7     Document Type: Article

References (44)

1. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97-101. (Pubitemid 24018107)
2. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728-9. (Pubitemid 44912208)
3. •• Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469-74. The latest comprehensive review of this topic.
4. Braithwaite SS, Barr WG, Rahman A, Quddusi S. Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies. Postgrad Med. 1998;104:163-6.
5. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12:358-62. (Pubitemid 44717593)
6. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005, (1):CD001288.
7. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284-9.
8. Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley PM. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax. 2009;64:857-62.
9. • Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96:1789-96. Once daily AM prednisolone's effect to elevate blood glucose only lasts for 14-18 hours. An observation with important implications for insulin therapy in these patients.
10. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001;41:1180-94. (Pubitemid 32983217)
11. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179-85. (Pubitemid 38325945)
12. •• Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2012 May 31. [Epub ahead of print] An important cautionary study that shows that although hyperglycemia may be associated with a negative outcome, correction of the hyperglycemia with intensive insulin therapy may not always improve the outcome.
13. • Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: Risk assessment and management. Diabetes Care. 2012;35:181-8. The latest comprehensive review of this complex evolving field.
14. Vincenti F, Friman S, Scheuermann E, et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus): Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506-14. (Pubitemid 46776239)
15. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69:588-95. (Pubitemid 43164454)
16. Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321-4. (Pubitemid 33026616)
17. Ganji MR, Charkhchian M, Hakemi M, Nederi GH, Solymanian T, Saddadi F, Amini M, Najafi I. Association of hyperglycemia on allograft function in the early period after renal transplantation. Transplant Proc. 2007;39:852-4. (Pubitemid 46764872)
18. Wallia A, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ, Levitsky J. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89:222-6.
19. •• Wallia A, Parikh ND, O'Shea-Mahler E, Schmidt K, DeSantis AJ, Tian L, Levitsky J, Molitch ME. Glycemic control by a glucose management service and infection rates after liver transplantation. Endocr Pract. 2011;17:546-51. An important study validating the benefits of excellent inpatient glucose control in the liver transplant population.
20. Dhital SM, Shenker Y, Meredith M, David DB. A Retrospective Study Comparing Neutral Protamine Hagedorn Insulin with Glargine as Basal Therapy in Prednisone-Associated Diabetes Mellitus in Hospitalized Patients. Endocr Pract. 2012 July 11, [Epub ahead of print].
21. • DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366-76. The follow-up study to the DCCT that shows continuing renal benefits of intensive control for patients with type 1 diabetes.
22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. (Pubitemid 351214285)
23. Williams ME, Lacson Jr E, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503-9. (Pubitemid 44527322)
24. Williams ME, Lacson Jr E, Wang W, Lazarus JM, Hakim R. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol. 2010;5:1595-601.
25. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049-55. (Pubitemid 46684623)
26. •• Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, Kalantar-Zadeh K. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61:708-15. Why we should aim for HBA1C 7 %-8% in our patients with diabetes and ESRD.
27. • Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171:1920-7. A large study of patients with diabetes and stage 3 and 4 chronic renal failure that shows that HBA1C less than 6.5 % or greater than 8 % are detrimental to patient outcome.
28. •• Kalantar-Zadeh K. A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Diabetes Care. 2012;35:1625-8. Why we should continue to use and trust HBA1C in patients with diabetes and ESRD.
29. Freedman BI. A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: Time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care. 2012;35:1621-4.
30. • Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, Fink JC. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1121-7. A comprehensive look at the risks and frequency of hypoglycemia in outpatients and inpatients with diabetes and renal failure.
31. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32:1153-7.
32. Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf. 2010;9:675-81.
33. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10:811-23.
34. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13:4-8.
35. Cano N. Bench-to-bedside review: glucose production from the kidney. Crit Care. 2002;6:317-21. (Pubitemid 34863698)
36. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391-8. (Pubitemid 351186278)
37. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med. 2003;20:642-5. (Pubitemid 36966558)
38. •• Park J, Lertdumrongluk P, Molnar MZ, Kovesdy CP, Kalantar-Zadeh K. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr Diab Rep. 2012;12:432-9. An excellent review of what happens to type 2 diabetes after patients develop ESRD and what goal HBA1C we should aim for in this population.
39. Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886-90. (Pubitemid 33636064)
40. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FW, Dornhorst A, Frost G, Turner JJ. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009;32:1137-42.
41. • Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, Biwole D, Kaze F, Gautier JF, Mbanya JC. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33:1409-12. A fascinating study showing that basal insulin requirements are 25 % less the day after hemodialysis in patients with ESRD and diabetes.
42. •• Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970-4. Reduction of initial glargine/glulisine insulin weight-based dosing (0.25 vs. 0.5 units/kg/day) in hospitalized patients with diabetes and renal insufficiency reduced the frequency of hypoglycemia by 50 % without compromising the control of hyperglycemia.
43. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-31.
44. •• Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, Seley JJ, Van den Berghe G. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16-38. The most up-to-date set of consensus guidelines for inpatients with diabetes.